SCHEMBL15970201

SCHEMBL15970201

Cc1ccc(S(=O)(=O)OCC2(CC#N)COC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.36
STAT3 P40763 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 2/20 0.34
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34
S100A4 P26447 1/20 0.34
MTOR P42345 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20455722 0.87 GLA (0.45) GLAL3MBTL1STAT3ALDH1A1MAPT
SCHEMBL690833 0.87 STAT3 (0.40) STAT3ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL15971922 0.87 L3MBTL1 (0.40) GLAL3MBTL1STAT3ALDH1A1MAPT
SCHEMBL18101 0.83 STAT3 (0.37) STAT3ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL24194808 0.82 STAT3 (0.39) STAT3ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL16572522 0.82 STAT3 (0.36) STAT3ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL30455226 0.81 GLA (0.38) GLAL3MBTL1STAT3ALDH1A1MAPT
SCHEMBL10950116 0.81 STAT3 (0.36) STAT3ALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL29906298 0.81 GLA (0.40) GLAL3MBTL1STAT3ALDH1A1MAPT
SCHEMBL2578056 0.78 PDE9A (0.36) STAT3ALDH1A1TDP1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10966980-B2 Pyrrolo[2,3-d]pyrimidine derivatives PFIZER INC. (US) 2021-04-06 US disclosed
EP-3180344-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE PFIZER (US) 2019-09-18 EP disclosed
EP-3290421-B1 COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) PFIZER (US) 2019-01-02 EP disclosed
EP-3290421-A1 COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) Pfizer Inc (US) 2018-03-07 EP disclosed
EP-2958921-B1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK) PFIZER (US) 2017-09-20 EP disclosed
EP-3180344-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE Pfizer Inc (US) 2017-06-21 EP disclosed
US-9549929-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2017-01-24 US disclosed
US-9545405-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2017-01-17 US disclosed
US-20160045508-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. (US) 2016-02-18 US disclosed
WO-2016024185-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE PFIZER INC. (US) 2016-02-18 WO disclosed
EP-2958921-A1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) Pfizer Inc. (US) 2015-12-30 EP disclosed
US-20150246048-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. 2015-09-03 US disclosed
US-20150225408-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. 2015-08-13 US disclosed
US-9035074-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2015-05-19 US disclosed
WO-2014128591-A1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) PFIZER INC. (US) 2014-08-28 WO disclosed
US-20140243312-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225408-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 GLA 4834/4885L3MBTL1 4224/4885STAT3 30/4885
US-20160045508-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 GLA 4790/4885L3MBTL1 4148/4885STAT3 26/4885
US-10966980-B2 Pyrrolo[2,3-d]pyrimidine derivatives JAK3, JAK1, JAK2 GLA 4790/4885L3MBTL1 4148/4885STAT3 26/4885
US-20150246048-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 GLA 4834/4885L3MBTL1 4224/4885STAT3 30/4885
US-20140243312-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 GLA 4834/4885L3MBTL1 4224/4885STAT3 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.